Logo

Alnylam Presents 18-Month Results of Vutrisiran in P-III (HELIOS-A) Study for the Treatment of hATTR Amyloidosis with Polyneuropathy

Share this
Alnylam Presents 18-Month Results of Vutrisiran in P-III (HELIOS-A) Study for the Treatment of hATTR Amyloidosis with Polyneuropathy

Alnylam Presents 18-Month Results of Vutrisiran in P-III (HELIOS-A) Study for the Treatment of hATTR Amyloidosis with Polyneuropathy

Shots:

  • The P-III (HELIOS-A) study evaluated the efficacy & safety of vutrisiran (25mg, SC, q3mos.) vs patisiran (0.3 mg/kg, IV, q3w) in a ratio (3:1) in 164 patients with hATTR amyloidosis with polyneuropathy across 57 sites in 22 countries
  • The trial met all 2EPs i.e., improvement in clinical EPs & non-inferiority in serum TTR reduction over patisiran, improvement in mNIS+7 (48% vs 4%), gait speed, nutritional status, QoL (57% vs 10%) & overall disability over PBO
  • The therapy also showed an improvement in exploratory cardiac EPs @18mos., including biomarker NT-proBNP, echocardiographic parameters & cardiac uptake of technetium on scintigraphy imaging along with promising safety profile

Ref: Businesswire | Image: Businesswire

Click here to­ read the full press release 

Tuba

Tuba was Senior Editor at PharmaShots. She was curious, creative, and passionate about recent updates and innovations in the life sciences industry. She covered Biopharma, MedTech, and Digital health segments. Tuba also had an experience in digital and social media marketing and ran the campaigns independently. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions